Practical considerations for managing patients being treated with topical roflumilast
Journal of Pharmacy & Pharmaceutical Sciences · 08.05.2026 · 29
DOI: 10.3389/jpps.2026.16026 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, online erschienen am 08.05.2026. Verfasst von Sameh Hanna und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology on Bloor, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Aminopyridines, Benzamides, Phosphodiesterase 4 Inhibitors. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Topical roflumilast, available in 0.3% cream, 0.15% cream, and 0.3% foam formulations, is a novel, highly potent phosphodiesterase-4 (PDE4) inhibitor that was recently approved in Canada for the treatment of plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, respectively. Topical formulations were shown in clinical trials to significantly improve disease symptoms with excellent tolerability and minimal adverse events. An oral form of roflumilast has also been approved in Canada since 2010 for the maintenance treatment of chronic obstructive pulmonary disease. The product monograph for topical roflumilast currently references a substantial amount of safety information specific to the oral formulation due to a lack of long-term safety data. Furthermore, no formal drug-drug interaction studies have been conducted with topical roflumilast, nor in special populations in whom oral roflumilast is contraindicated. Due to the impact that the route of administration has on the pharmacokinetic profile of a drug and its subsequent ability to produce undesirable or toxic effects, this presents a challenge for pharmacists who are tasked with determining how to best interpret and communicate this safety information to patients. This paper reviews the safety information contained within the product monograph for topical roflumilast in the context of the pharmacokinetic differences between the topical and oral formulations. The impact of the route of administration on adverse effect risk, drug-drug interactions, and contraindications is highlighted, and practical guidance is provided to assist pharmacists in interpreting and applying this information in practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology on Bloor, Toronto, ON, Canada.
- Division of Dermatology, Temerty School of Medicine, University of Toronto, Toronto, ON, Canada.
- UPharmacy, Edmonton, AB, Canada.
- Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
- Division of Dermatology, University of Calgary, Calgary, AB, Canada.
- Beacon Dermatology, Calgary, AB, Canada.
Zitieren
APA
Hanna, S., Chehade, A., Han, C., Poelman, S., Sanghera, R., Whiskin, C., & Sihota, A. (2026). Practical considerations for managing patients being treated with topical roflumilast. Journal of Pharmacy & Pharmaceutical Sciences, 29. https://doi.org/10.3389/jpps.2026.16026
Vancouver
Hanna S, Chehade A, Han C, Poelman S, Sanghera R, Whiskin C, et al. Practical considerations for managing patients being treated with topical roflumilast. Journal of Pharmacy & Pharmaceutical Sciences. 2026;29. doi:10.3389/jpps.2026.16026
BibTeX
@article{Hanna2026,
author = {Hanna, Sameh and Chehade, Ahmad and Han, Christina and Poelman, Susan and Sanghera, Ravina and Whiskin, Carolyn and Sihota, Aaron},
title = {Practical considerations for managing patients being treated with topical roflumilast},
journal = {Journal of Pharmacy & Pharmaceutical Sciences},
year = {2026},
volume = {29},
doi = {10.3389/jpps.2026.16026}
}
EUVIMED